BridgeBio Pharma Profit Margin

BridgeBio Pharma (BBIO) currently reports a profit margin of -1.28% as of March 2026. That compares with -5.24% in the prior-year period — up 75.5% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore BridgeBio Pharma's profit margin history and peer comparisons.

BridgeBio Pharma's profit margin increased from -5.24% to -1.28% — a 75.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma's profit margin of -1.28% is lower than the Healthcare sector average of 15.58%. That is roughly 922.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BridgeBio Pharma's current -1.28% should be judged against Healthcare norms (sector average: 15.58%) and against BBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.